Has the Centers for Medicare Medicaid Services implicitly adopted a value framework for Medicare drug price negotiations?

15 December 2023 - The US Inflation Reduction Act of 2022 created several major policy changes to the pricing of prescription ...

Read more →

Evolving our approach to COVID-19 vaccines and treatments

6 December 2023 - As New Zealand’s response to the COVID-19 pandemic has evolved, so has ours. ...

Read more →

PHARMAC’s new equity policy

6 December 2023 - PHARMAC is drafting its first Equity Policy which outlines the mahi PHARMAC does, can do, or needs ...

Read more →

Funding verdict looms on ‘future of cancer therapy’

21 November 2023 - The chance of survival for hundreds of Australians living with a deadly type of blood cancer ...

Read more →

Informing real-time decisions with post-market drug evidence

10 November 2023 - It’s been one year since CADTH launched the Post-Market Drug Evaluation (PMDE) Program to provide decision-makers with ...

Read more →

PHARMAC needs to work for patients, not itself

10 October 2023 - “The internal chaos and siege mentality at PHARMAC is exactly why the next Government needs to ...

Read more →

Incorporating added therapeutic benefit and domestic reference pricing into Medicare payment for expensive Part B drugs

10 September 2023 - A retrospective analysis using a 20% nationally representative sample of 2015 to 2019 traditional Medicare Part B ...

Read more →

Protecting Medicare’s discretion to say no to unproven therapies

8 September 2023 - Medicare, the largest health care payer in the nation, is also the single biggest source of revenue ...

Read more →

Review of cancer related surrogate outcomes used for PBAC decision-making

8 September 2023 - Surrogate outcome measures have an increasingly important role in cancer medicine research providing evidence to support ...

Read more →

Australia knocks back application for diabetes drug that could overshadow Ozempic

29 August 2023 - Australia has knocked back an application to subsidise the diabetes drug Mounjaro but the manufacturer still wants ...

Read more →

In the case of a devastating disease, the FDA weighs an experimental drug’s muddled data and a desperate need

14 August 2023 - Emma Albee knows the experimental drug she takes is not a cure. It won’t allow her ...

Read more →

PHARMAC’s funding model creating an ‘ethical dilemma’ - specialist

29 July 2023 - The New Zealand Breast Cancer Foundation is renewing calls for PHARMAC to fund Keytruda for the ...

Read more →

Statutory authority for Medicare coverage decisions - CMS is an independent federal agency

28 July 2023 - It is time for the public to recognize and strongly support the authority of the US Centers ...

Read more →

Pilot expert committee to support decision-making across the drug life cycle

8 June 2023 - CADTH, Canada’s drug and health technology agency, announces the creation and inaugural membership of a new ...

Read more →

A review of HTA guidelines on societal and novel value elements

25 May 2023 - Health technology assessment organisations vary in terms of how they conduct assessments.  ...

Read more →